Home NDC 53002-1777 VyLibra
Product NDC 53002-1777
11-digit product format 530021777
Labeler code 53002
Product ID 53002-1777_b8da0c3e-bddd-401c-b973-039574a2ffbd
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name norgestimate and ethinyl estradiol
Dosage form KIT
Labeler RPK Pharmaceuticals, Inc.
Application ANDA205449
Marketing category ANDA
Marketing start 2016-07-07
Marketing end 0000-00-00
Active strength 0
NDC exclude flag No
Listing certified through 2021-12-31
Current FDA listing Historical FDA.report record Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 36 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Package NDC Code Status Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 excluded product product I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 53002-1777-6 I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 53002-1777-1 I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 53002-1777-3 I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 excluded product product I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 53002-1777-6 I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 53002-1777-1 I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 53002-1777-3 I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-04-01 02:39 UTC · source 2025-03-31 excluded product product I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 53002-1777-6 I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 53002-1777-1 I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 53002-1777-3 I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-03-28 20:22 UTC · source 2025-03-28 excluded product product I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 53002-1777-6 I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 53002-1777-1 I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 53002-1777-3 I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-22 03:12 UTC · source 2025-03-21 excluded product product I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 53002-1777-6 I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 53002-1777-1 I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 53002-1777-3 I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-10 12:48 UTC · source 2025-03-10 excluded product product I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 53002-1777-6 I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 53002-1777-1 I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 53002-1777-3 I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-02-02 03:52 UTC · source 2025-01-31 excluded product product U Excluded because listing certification expired 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 53002-1777-6 U Excluded because listing certification expired 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 53002-1777-3 U Excluded because listing certification expired 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 53002-1777-1 U Excluded because listing certification expired 302b2466d912…e7b80fea0513…2025-01-20 13:05 UTC · source 2025-01-20 excluded product product U Excluded because listing certification expired ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 53002-1777-6 U Excluded because listing certification expired ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 53002-1777-3 U Excluded because listing certification expired ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 53002-1777-1 U Excluded because listing certification expired ed331223b511…672a5bd82f5f…2025-01-11 03:41 UTC · source 2025-01-10 excluded product product U Excluded because listing certification expired 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 53002-1777-6 U Excluded because listing certification expired 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 53002-1777-3 U Excluded because listing certification expired 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 53002-1777-1 U Excluded because listing certification expired 0efc9e666f02…f202fb6c5f17…
Source provenance: Browse the complete Orange Book source catalog · source snapshot 42 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date A205449-001 MILI ETHINYL ESTRADIOL; NORGESTIMATE 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 1 matching rows.
Application-product, TE code table Application-product TE code A205449-001 AB
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 2 · 42 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-08-18 06:07:40 2026-07 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 87673890dc5c…2021-03-12 10:30 UTC 2021-03 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 3f01610625f2…2019-09-15 20:21 UTC 2019-09 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 b00525d2431f…2019-07-19 19:46 UTC 2019-07 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 ea99ee380514…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 053a50430f4f…2023-01-26 05:58 UTC 2023-01 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 3bdfa0b2c4d7…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 A205449-001 MILI 0.035MG;0.25MG TABLET / ORAL-28 AB 2016-07-07 e64feba35796…
Observed Orange Book normalized TE history# Normalized TE history page 1 of 2 · 42 observed states.
DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# NDC, Effective, Related label table NDC Effective Related label 53002-1777-1 2025-01-30 These highlights do not include all the information needed to use VyLibra safely and effectively. See full prescribing information for VyLibra. VyLibra ® (norgestimate and ethinyl estradiol) tablets, for oral use Initial U.S. Approval: 1989 53002-1777-3 2025-01-30 These highlights do not include all the information needed to use VyLibra safely and effectively. See full prescribing information for VyLibra. VyLibra ® (norgestimate and ethinyl estradiol) tablets, for oral use Initial U.S. Approval: 1989 53002-1777-6 2025-01-30 These highlights do not include all the information needed to use VyLibra safely and effectively. See full prescribing information for VyLibra. VyLibra ® (norgestimate and ethinyl estradiol) tablets, for oral use Initial U.S. Approval: 1989 53002-1777-1 2023-06-07 These highlights do not include all the information needed to use VyLibra safely and effectively. See full prescribing information for VyLibra. VyLibra ® (norgestimate and ethinyl estradiol) tablets, for oral use Initial U.S. Approval: 1989 53002-1777-3 2023-06-07 These highlights do not include all the information needed to use VyLibra safely and effectively. See full prescribing information for VyLibra. VyLibra ® (norgestimate and ethinyl estradiol) tablets, for oral use Initial U.S. Approval: 1989 53002-1777-6 2023-06-07 These highlights do not include all the information needed to use VyLibra safely and effectively. See full prescribing information for VyLibra. VyLibra ® (norgestimate and ethinyl estradiol) tablets, for oral use Initial U.S. Approval: 1989 53002-1777-1 2023-01-30 These highlights do not include all the information needed to use VyLibra safely and effectively. See full prescribing information for VyLibra. VyLibra ® (norgestimate and ethinyl estradiol) tablets, for oral use Initial U.S. Approval: 1989 53002-1777-3 2023-01-30 These highlights do not include all the information needed to use VyLibra safely and effectively. See full prescribing information for VyLibra. VyLibra ® (norgestimate and ethinyl estradiol) tablets, for oral use Initial U.S. Approval: 1989 53002-1777-6 2023-01-30 These highlights do not include all the information needed to use VyLibra safely and effectively. See full prescribing information for VyLibra. VyLibra ® (norgestimate and ethinyl estradiol) tablets, for oral use Initial U.S. Approval: 1989
DailyMed Package Descriptions# DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 53002-1777 VYLIBRA (NORGESTIMATE AND ETHINYL ESTRADIOL) KIT [RPK PHARMACEUTICALS, INC.] 3 Legacy NDC, 5 package rows 20230609_e5b71df3-d99e-4e2d-a0cf-4c2790a6907d.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 2 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Marketing end Sample Exclude flag Status 53002-1777-1 53002177701 1 KIT in 1 BLISTER PACK (53002-1777-1) 1 kit 2019-01-01 0000-00-00 No No Current 53002-1777-3 53002177703 3 BLISTER PACK in 1 POUCH (53002-1777-3) > 1 KIT in 1 BLISTER PACK 3 blister pack 2019-01-01 0000-00-00 No No Current 53002-1777-6 53002177706 6 BLISTER PACK in 1 POUCH (53002-1777-6) > 1 KIT in 1 BLISTER PACK 6 blister pack 2019-01-01 0000-00-00 No No Current